IPOGrid
0001327273
IPO filing research
Lyra Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · LYRA
follow-on
priced
Nasdaq Capital Market
EFFECT
Lyra Therapeutics, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: EFFECT on 2026-03-26. Current deal snapshot: exchange Nasdaq Capital Market.
Filing Timeline
SEC EDGAR
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
Lyra Therapeutics, Inc. announced the effectiveness of its registration statement on March 26, 2026, following a Phase 3 trial (ENLIGHTEN 2) for its lead candidate LYR-210, a bioabsorbable nasal insert for chronic rhinosinusitis (CRS). The trial met primary and secondary endpoints, showing significant symptom improvement. The company also executed a securities purchase agreement in June 2025, issuing shares and warrants to selling securityholders. LYR-210's efficacy and safety profile, along with its potential to address a large patient population, are central to its value proposition.
2026-03-26 · 9999999995-26-000939
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
Lyra Therapeutics, Inc. filed a Notice of Effectiveness for its IPO on March 26, 2026, with a revised submission type (POS AM) compared to its previous filing. The current filing includes updated accessional and file numbers, indicating a formalized or corrected submission.
2026-03-26 · 9999999995-26-000936
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
Lyra Therapeutics, Inc. received effectiveness for its registration statement on March 26, 2026. The filing reflects a post-effective amendment (POS AM) with updated identifiers compared to a prior submission, though no substantive content differences are visible in the provided text.
2026-03-26 · 9999999995-26-000934
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows CERT and confirms the priced prospectus.
846,744 shares
Common Stock · Exchange Nasdaq Capital Market · Ticker LYRA · Selling stockholders only · Use of proceeds The company will not receive any proceeds from the sale of common stock by the selling securityholders.
Lyra Therapeutics, Inc. is registering the resale of 846,744 shares of common stock issuable upon exercise of warrants, with no proceeds going to the company. The filing includes details about the ENLIGHTEN 2 Phase 3 trial results for LYR-210, a bioabsorbable nasal insert for chronic rhinosinusitis, and a securities purchase agreement from June 2025 involving common stock and warrants. The company emphasizes risks related to clinical trials, regulatory approvals, and commercialization.
2025-07-31 · 0001193125-25-169573
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1 and marks the registration effective.
Lyra Therapeutics, Inc. has received SEC approval for its IPO, with the registration statement declared effective on July 30, 2025. The filing confirms the company's ability to proceed with the offering of 846,744 shares of common stock by selling securityholders, following the initial S-1 registration on July 22, 2025. The company, a clinical-stage biotechnology firm focused on anti-inflammatory therapies for chronic rhinosinusitis, emphasizes risks related to clinical trials, regulatory approval, and market competition.
2025-07-30 · 9999999995-25-002415
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows EFFECT in the pre-IPO sequence.
846,744 shares
Common Stock of Lyra Therapeutics, Inc. · Exchange Nasdaq Capital Market · Ticker LYRA · Selling stockholders only · Use of proceeds No proceeds to the company; selling stockholders are offering shares
Lyra Therapeutics, Inc. filed an S-1 registration statement for a securities offering by selling securityholders, including 846,744 shares of common stock and warrants. The company, a clinical-stage biotechnology firm focused on anti-inflammatory therapies for chronic rhinosinusitis (CRS), highlights positive Phase 3 trial results for its lead candidate LYR-210. The offering follows a private placement in June 2025 and includes a registration statement for resale of warrants. Lyra emphasizes its bioabsorbable nasal insert technology and ongoing regulatory discussions, though it notes risks related to clinical trial outcomes and market competition.
2025-07-22 · 0001193125-25-162669
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 8-A12B and confirms the priced prospectus.
Price $11.81 · 273,012 shares · Gross proceeds $4,999,873
Common Stock · Exchange Nasdaq Capital Market · Ticker LYRA · Share and two Private Warrants · Pre-Funded Warrants to purchase 150,360 shares at $0.001 each, plus Private Warrants exercisable at $11.56 · Flags warrants
Lyra Therapeutics, Inc. is offering 273,012 shares of common stock and pre-funded warrants to purchase 150,360 shares, with an offering price of $11.81 per share and $11.809 per pre-funded warrant. The proceeds, estimated at $4.4 million, will fund working capital, clinical development, and pre-commercialization expenses for LYR-210, a bioabsorbable nasal insert for chronic rhinosinusitis. The offering follows positive Phase 3 trial results for LYR-210, though previous Phase 3 trials showed mixed outcomes. The company lacks a public trading market for its securities, and the placement agent is H.C. Wainwright & Co., LLC.
2025-06-27 · 0001193125-25-150155
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows S-1/A and confirms the priced prospectus.
Common Stock · Exchange NASDAQ · Ticker LYRA · Underwriters Cantor Fitzgerald & Co.
The current 424B5 filing suspends Lyra Therapeutics' ATM Program and terminates the continuous offering under the ATM Prospectus effective June 26, 2025. The company has sold 7,059,228 shares via the ATM Program since March 2024, raising $24.8 million. The Agreement with Cantor Fitzgerald & Co. remains active but no further sales will occur without a new prospectus supplement.
2025-06-26 · 0001193125-25-148886
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
Lyra Therapeutics, Inc. has received effectiveness for its S-3 registration statement, enabling the company to offer up to $50 million in common stock through a controlled equity offering program. The offering, managed by Cantor Fitzgerald & Co. as sales agent, allows for at-the-market sales of shares, with Cantor acting as an underwriter. The filing incorporates by reference prior SEC filings and highlights risks associated with the company's clinical-stage biotechnology operations.
2024-04-01 · 9999999995-24-000816
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
Gross proceeds $50,000,000
common · Exchange Nasdaq · Ticker LYRA · Underwriters Cantor Fitzgerald & Co.
Lyra Therapeutics, Inc. has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to offer and sell up to $50 million in common stock through an at-the-market offering. This prospectus supplement updates the previous filing (424B3) by introducing the new sales mechanism, emphasizing the role of Cantor as the sales agent and underwriter. The company remains a clinical-stage biotechnology firm focused on developing localized therapies for chronic rhinosinusitis, with ongoing Phase 3 and Phase 2 trials for LYR-210 and LYR-220.
2023-09-01 · 0001193125-23-227619
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
The SEC has declared the S-3 registration statement effective for Lyra Therapeutics, Inc., allowing selling securityholders to offer up to 15,521,322 shares of common stock. The filing includes shares from existing holdings and warrants, with no proceeds going to the company. The prospectus provides general securities details, with specific terms to be outlined in supplements.
2023-07-07 · 9999999995-23-002032
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows DRS/A and confirms the priced prospectus.
21,967,353 shares
Common Stock · Exchange Nasdaq Global Market · Ticker LYRA · Warrants to purchase common stock · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will go to the company; no proceeds from selling stockholders' shares
Lyra Therapeutics, Inc. is offering up to 21,967,353 shares of common stock through selling securityholders, including 12,236,714 currently issued shares and 9,730,639 shares from warrants. The company will not receive proceeds from stock sales but will benefit from warrant exercises. The prospectus outlines risks, clinical trial updates for LYR-210 and LYR-220, and distribution methods involving underwriters, dealers, or direct sales.
2023-07-07 · 0001193125-23-183840
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
Lyra Therapeutics, Inc. filed a Notice of Effectiveness for its Form S-3 registration statement, enabling the company to offer up to $50 million in common stock through an At-the-Market (ATM) program with Jefferies LLC as the sales agent. The filing confirms the effectiveness of the registration, allowing ongoing sales of shares under the previously disclosed terms.
2022-05-20 · 9999999995-22-001554
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows DRS/A and confirms the priced prospectus.
15,521,322 shares · Gross proceeds $0.00
Common · Exchange Nasdaq Global Market · Ticker LYRA · 5,000,000 shares issuable upon exercise of warrants · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds
Lyra Therapeutics, Inc. filed a 424B3 prospectus supplement to disclose details about the offering of 15,521,322 common shares by selling securityholders. The prospectus outlines that Lyra will not receive proceeds from the sale, with shares including 10,521,322 currently issued and 5,000,000 issuable via warrants. The filing emphasizes the company's focus on ENT disease treatments and references incorporated SEC filings for additional context.
2022-05-20 · 0001193125-22-156250
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows DRS and confirms the priced prospectus.
Gross proceeds $50,000,000
Common Stock · Exchange Nasdaq Global Market · Ticker LYRA · Underwriters Jefferies LLC
Lyra Therapeutics, Inc. is offering up to $50 million in common stock through an at-the-market offering via Jefferies LLC, acting as sales agent. The company, listed on Nasdaq under 'LYRA,' focuses on developing localized treatments for ear, nose, and throat (ENT) diseases using its XTreo™ platform. The offering includes a 3% commission for Jefferies and references risk factors related to clinical-stage operations, regulatory approvals, and market competition.
2021-05-25 · 0001193125-21-171195
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B4 and marks the registration effective.
Lyra Therapeutics, Inc. has received effectiveness for its S-3 registration statement, enabling the issuance of 3,500,000 shares of common stock at $16.00 per share. The offering, previously disclosed in a 424B4 filing, includes underwriters BofA Securities, Jefferies, and William Blair. The company focuses on developing localized drug delivery solutions for ENT diseases, with lead candidates LYR-210 and LYR-220 targeting chronic rhinosinusitis.
2021-05-20 · 9999999995-21-002044
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $16.00 · 3,500,000 shares · Gross proceeds $56,000,000
Common Stock · Exchange Nasdaq Global Market · Ticker LYRA · Over-allotment 525,000 · Underwriters BofA Securities, Jefferies, William Blair
Lyra Therapeutics, Inc. is conducting an initial public offering (IPO) of 3,500,000 shares of common stock at $16.00 per share, with proceeds of $52,080,000 before expenses. The company, an emerging growth company, focuses on developing novel drug and delivery solutions for ear, nose, and throat (ENT) diseases using its XTreo platform. Its lead candidates, LYR-210 and LYR-220, target chronic rhinosinusitis (CRS) with sustained drug delivery. The Phase 2 trial for LYR-210 was impacted by COVID-19, leading to halted enrollment. The shares are listed on Nasdaq under 'LYRA' with underwriters including BofA Securities, Jefferies, and William Blair.
2020-05-01 · 0001193125-20-131089
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 8-A12B and marks the registration effective.
Lyra Therapeutics, Inc. became effective for its initial public offering (IPO) on April 30, 2020, under Form S-1. The filing registers common stock for trading on The Nasdaq Stock Market LLC, following prior registration under Form 8-A12B for Section 12(b) of the Securities Exchange Act. The S-1 includes the prospectus and registration statement details for the IPO.
2020-04-30 · 9999999995-20-000931
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
The current filing for Lyra Therapeutics, Inc. appears to be a CERT form dated April 30, 2020, with limited readable content. The previous filing was an EFFECT form (notice of effectiveness) for an S-1 registration statement. No substantive details about the company's operations, financials, or offering terms are visible in the provided text.
2020-04-30 · 0001354457-20-000171
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Range $14.00 to $16.00 · 3,500,000 shares · Gross proceeds $64,400,000
Common Stock · Exchange Nasdaq Global Market · Ticker LYRA · Over-allotment 525,000 · Use of proceeds Proceeds will be used for working capital, research and development, and other general corporate purposes · Underwriters BofA Securities, Jefferies, William Blair
Lyra Therapeutics, Inc. is conducting an initial public offering (IPO) to raise up to $64.4 million by selling 3,500,000 shares of common stock at an expected price range of $14.00 to $16.00 per share. The company develops localized drug delivery solutions for ear, nose, and throat (ENT) diseases using its XTreo platform. Its lead candidates, LYR-210 and LYR-220, aim to treat chronic rhinosinusitis (CRS) with sustained drug release. LYR-210 is in a Phase 2 trial (LANTERN), with topline data expected by late 2020, while LYR-220 is in development for CRS patients with nasal anatomical changes. The offering is led by underwriters including BofA Securities, Jefferies, and William Blair.
2020-04-27 · 0001193125-20-120337
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
Lyra Therapeutics, Inc. filed Form 8-A12B to register its common stock under Section 12(b) of the Securities Exchange Act of 1934, referencing its prior S-1 registration statement. The filing incorporates by reference the description of its capital stock from the S-1, which outlines its clinical-stage focus on developing integrated drug and delivery solutions for ENT diseases, with initial product candidates LYR-210 and LYR-220 targeting chronic rhinosinusitis. The company expects its shares to trade on Nasdaq under the symbol 'LYRA' following the offering.
2020-04-27 · 0001193125-20-120286
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common Stock · Exchange Nasdaq Global Market · Ticker LYRA · Underwriters BofA Securities, Jefferies, William Blair
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel drug and delivery solutions for ear, nose, and throat (ENT) diseases, particularly chronic rhinosinusitis (CRS). The company's proprietary XTreo platform enables sustained, localized drug delivery via bioresorbable polymeric matrices. LYR-210 and LYR-220 are in clinical trials for CRS, with LYR-210 in a Phase 2 trial (LANTERN) and LYR-220 advancing to a proof-of-concept trial. The company is conducting an initial public offering (IPO) to raise up to $57.5 million, with shares expected to trade on Nasdaq under 'LYRA'.
2020-03-06 · 0001193125-20-065213
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
Lyra Therapeutics, Inc. is conducting its initial public offering (IPO) to raise capital for the development and commercialization of its novel drug delivery platform, XTreo, focused on treating ear, nose, and throat (ENT) diseases. The company's lead product candidates, LYR-210 and LYR-220, are bioresorbable matrices designed to deliver sustained drug therapy for chronic rhinosinusitis (CRS). The IPO involves the sale of common stock, with underwriters including BofA Securities, Jefferies, and William Blair. The filing highlights the company's emerging growth status, clinical trial progress, and risks associated with its reliance on a single product pipeline.
2020-02-14 · 0000950123-20-002595
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
Lyra Therapeutics, Inc. is conducting an initial public offering (IPO) to raise capital, registering common stock under Form S-1. The company is a clinical-stage biotechnology firm focused on developing novel drug and delivery solutions for ear, nose, and throat (ENT) diseases using its proprietary XTreo platform. The offering includes product candidates LYR-210 and LYR-220 for chronic rhinosinusitis (CRS), with anticipated trading on the Nasdaq Global Market under 'LYRA.' The filing outlines underwriters (BofA Securities, Jefferies, William Blair, BTIG) and highlights risks related to clinical trials, regulatory approval, and market competition.
2019-12-19 · 0000950123-19-011977
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel drug and delivery solutions for localized treatment of ear, nose, and throat (ENT) diseases. The company's proprietary XTreo platform enables sustained, targeted delivery of therapeutics via bioresorbable polymeric matrices. Its lead candidates, LYR-210 and LYR-220, are designed to provide up to six months of continuous drug therapy for chronic rhinosinusitis (CRS) patients. The company is preparing for its initial public offering (IPO), with shares expected to trade on the Nasdaq Global Market under the symbol LYRA. Lyra is an emerging growth company subject to reduced disclosure requirements.
2019-11-08 · 0000950123-19-010418
Comparable Deals
5 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 5 using nearest neighbors.
Recent News
No recent news stored for this issuer.